Đ¡ĐμÑ€Đ³ĐμĐ¹ ФиÑ,иĐ»ĐμĐ²

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1626666/publications.pdf

Version: 2024-02-01

33 papers 7,986 citations

8 h-index 24 g-index

35 all docs 35 docs citations

35 times ranked 13582 citing authors

#	Article	IF	CITATIONS
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	27.0	6,227
2	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
3	Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 2268-2276.	27.0	547
4	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2013, 15, 1062-1073.	7.1	358
5	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	2.7	88
6	Trimetazidine in Angina Combination Therapy-The TACT Study: Trimetazidine versus Conventional Treatment in Patients with Stable Angina Pectoris in a Randomized, Placebo-Controlled, Multicenter Study. American Journal of Therapeutics, 2005, 12, 35-42.	0.9	76
7	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2018, 20, 760-768.	7.1	62
8	Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study. Vaccines, 2020, 8, 652.	4.4	29
9	PHARMACOEPIDEMIOLOGY AND THE EFFICACY OF ANTIHYPERTENSIVE TREATMENT IN REAL-LIFE PRACTICE OF THE CARDIOLOGY REFERRAL CLINIC. Rational Pharmacotherapy in Cardiology, 2015, 11, 8-17.	0.8	8
10	Medication adherence in patients with stable coronary artery disease in primary care. Research Results in Pharmacology, 2020, 6, 97-103.	0.4	7
11	Drug interchangeability: Clinical efficacy and safety. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2017, 9, 4-10.	1.2	6
12	Adherence to Medical Treatment in Elderly Patients with Coronary Artery Disease in the Settings of Primary Outpatient Care. Rational Pharmacotherapy in Cardiology, 2021, 17, 178-185.	0.8	4
13	SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES AMONG PATIENTS OF DIFFERENT AGE GROUPS WITH A HISTORY OF MYOCARDIAL INFARCTION BY THE EXAMPLE OF OUTPATIENT CARDIOLOGY INSTITUTION. Rational Pharmacotherapy in Cardiology, 2017, 13, 317-322.	0.8	3
14	Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of GlurazimÂ $^{\circ}$ (imiglucerase) in comparison with the reference product in healthy volunteers. Oncogematologiya, 2019, 14, 73-83.	0.3	3
15	Effects of Pharmacy Care Program on medication adherence in outpatients with stable coronary artery disease: a randomized controlled study. Cardiovascular Therapy and Prevention (Russian) Tj ETQq1 1 0.784	43 1.4 rgBT	Coverlock 10
16	EVALUATION OF THE REGULARITY OF ANTIHYPERTENSIVE DRUGS USAGE AS A COMPONENT OF TREATMENT ADHERENCE IN OUTPATIENTS OF A SPECIALIZED CARDIOLOGY CENTER. Rational Pharmacotherapy in Cardiology, 2015, 11, 238-246.	0.8	2
17	Critical aspects of the management of stable coronary artery disease in primary care practice or how to increase the efficacy of evidence-based pharmacological therapy?. Research Results in Pharmacology, 2020, 6, 15-20.	0.4	2
18	Lipid-lowering therapy in patients with coronary artery disease in primary care practices: what has changed over 7 years?. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2609.	1.4	2

#	Article	IF	CITATIONS
19	P102 Differential antiviral effect of porcine interferon alpha subtypes on classical swine fever virus infection of porcine monocytes. Cytokine, 2012, 59, 552.	3.2	1
20	FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY). Rational Pharmacotherapy in Cardiology, 2018, 14, 244-251.	0.8	1
21	Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease. Rational Pharmacotherapy in Cardiology, 2021, 17, 29-35.	0.8	1
22	Implementation of the concept of standard operating procedures into primary care practice: utopia or urgent need?. Kachestvennaya Klinicheskaya Praktika, 2020, , 75-84.	0.5	1
23	Lipid-lowering therapy in outpatients of different ages with coronary artery disease. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2654.	1.4	1
24	Safety, pharmacokinetics and pharmacodynamics of an original glycoprotein IIb/IIIa inhibitor in healthy volunteers: results of the clinical trial. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3033.	1.4	1
25	Antiarrhythmic effects of KLN-93, dicaine, and lidocaine in neurogenic atrial fibrillation. Bulletin of Experimental Biology and Medicine, 1997, 124, 688-690.	0.8	O
26	Effect of KLN-93 on ventricular fibrillation induced by reperfusion and electrical stimulation in cats. Bulletin of Experimental Biology and Medicine, 1997, 124, 738-740.	0.8	0
27	PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC STUDIES OF ANTIHYPERTENSIVE TREATMENT IN RUSSIA. Analytical Review. Rational Pharmacotherapy in Cardiology, 2013, 9, 66-73.	0.8	O
28	PP.30.37. Journal of Hypertension, 2015, 33, e409.	0.5	0
29	[PP.35.02]. Journal of Hypertension, 2015, 33, e450.	0.5	O
30	SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY). Rational Pharmacotherapy in Cardiology, 2017, 13, 171-177.	0.8	0
31	Pharmacokinetics, pharmacodynamics, and tolerability of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase I study with dose escalation in healthy volunteers Journal of Clinical Oncology, 2012, 30, 9060-9060.	1.6	0
32	CHANGE OF HYPERTENSION TREATMENT SCHEME IN OUTPATIENT CARE AT SPECIALIZED CARDIOLOGIC INSTITUTION, AND FACTORS ASSOCIATED WITH THE CHANGE OF ANTIHYPERTENSION THERAPY. Russian Journal of Cardiology, 2015, , 100.	1.4	0
33	Analysis of changes in pharmacotherapy of stable angina over the five-year period at specialized out-patient level of medical care (pharmacoepidemiological study). Research Results in Pharmacology, 2018, 4, 47-58.	0.3	0